“…Accordingly, an emerging trend is the development of reversible covalent inhibitors which provide potent inhibition of the desired target, but will not permanently inactivate off-target proteins . Among the reversible covalent warheads explored for cruzain to date, an aldehyde group often, if not always, affords outstanding inhibitory potency compared to α-keto amides, nitriles, oximes, heterocycles, and so on. − On the other hand, the inherent electrophilicity of aldehydes contributes to their rapid metabolism, immunotoxicities, and untoward drug–drug interactions, which have all but disqualified their use in drug design. Theoretically, these issues can be mitigated by confining the exposure of the aldehyde solely to the germane protein target while eschewing off-target proteins; however, such approaches have been challenging to implement …”